Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BBT-176 + Cetuximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BBT-176||BBT176|BBT 176||EGFR Inhibitor 4th gen 13||BBT-176 is a 4th generation EGFR inhibitor with enhanced activity against C797S-containing EGFR triple mutants, potentially leading to tumor growth inhibition (PMID: 37249619).|
|Cetuximab||Erbitux||IMC-C225||EGFR Antibody 54||Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|